Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database.

Scirè CA, Caporali R, Sarzi-Puttini P, Frediani B, Di Franco M, Tincani A, Sinigaglia L, Sfriso P, Tirri R, Bellis E, Delsante G, Porru G, Salaffi F, Giuggioli D, Rossini M, Todoerti M, Bazzichi L, Govoni M, Gerli R, Raschetti R, Minisola G, Montecucco C, Todesco S; Monitornet project.

Clin Exp Rheumatol. 2013 Nov-Dec;31(6):857-63. Epub 2013 Aug 26.

PMID:
23981363
2.

Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.

Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL.

Arthritis Care Res (Hoboken). 2016 Apr;68(4):432-9. doi: 10.1002/acr.22788.

3.

Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.

Arstikyte I, Kapleryte G, Butrimiene I, Venalis A.

Biomed Res Int. 2015;2015:604872. doi: 10.1155/2015/604872. Epub 2015 Apr 27.

4.

Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.

Fafá BP, Louzada-Junior P, Titton DC, Zandonade E, Ranza R, Laurindo I, Peçanha P, Ranzolin A, Hayata AL, Duarte A, Silveira IG, Costa I, Macieira JC, Guedes-Barbosa LS, Bertolo MB, Sauma MF, Silva MB, Freire M, Scheinberg MA, Fernandes V, Bianchi W, Miranda JR, Pinheiro GR, Carvalho HM, Brenol CV, Pereira IA, de Castro GR, de Morais JC, Oliveira SK, de Abreu MM, Toledo RA, Pinheiro MM, Vieira WP, Valim V; BIOBADABRASIL.

Clin Rheumatol. 2015 May;34(5):921-7. doi: 10.1007/s10067-015-2929-7. Epub 2015 Apr 8.

PMID:
25851594
5.

Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.

Spadaro A, Punzi L, Marchesoni A, Lubrano E, Mathieu A, Cantini F, Olivieri I, Salvarani C, Scarpa R, Scrivo R, Ramonda R, Porru G, D'Angelo S, Catanoso M, Atteno M, Valesini G.

Rheumatology (Oxford). 2010 Jun;49(6):1107-11. doi: 10.1093/rheumatology/keq008. Epub 2010 Mar 11.

PMID:
20223813
6.

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

Carmona L, Gómez-Reino JJ; BIOBADASER Group.

Arthritis Res Ther. 2006;8(3):R72. Epub 2006 Apr 18.

7.

Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.

Favalli EG, Selmi C, Becciolini A, Biggioggero M, Ariani A, Santilli D, Fusaro E, Parisi S, Massarotti M, Marchesoni A, Meroni PL.

Arthritis Care Res (Hoboken). 2017 Jun;69(6):867-874. doi: 10.1002/acr.23090.

8.

Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.

Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register.

Arthritis Rheum. 2007 Jan;56(1):13-20.

9.

Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.

García-Lagunar MH, Gutiérrez-Cívicos MR, García-Simón MS, Conesa-Zamora P, Jimenez-Santos E, Cano-Vivar P, García-Márquez A, Muñoz-García I, Viney AC.

Ann Pharmacother. 2017 May;51(5):388-393. doi: 10.1177/1060028016682330. Epub 2016 Dec 5.

PMID:
27920336
10.

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.

Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians.

Arthritis Rheum. 2009 May 15;61(5):560-8. doi: 10.1002/art.24463.

11.

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; B S R B R Control Centre Consortium, Symmons DP; BSR Biologics Register.

Ann Rheum Dis. 2010 Mar;69(3):522-8. doi: 10.1136/ard.2009.118935. Epub 2009 Oct 22.

12.

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.

J Rheumatol. 2011 Jul;38(7):1273-81. doi: 10.3899/jrheum.101142. Epub 2011 May 15.

PMID:
21572150
13.

Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.

Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L, D'Onofrio F, Marsico A, Carlino G, Casilli O, Cacciapaglia F, Zuccaro C, Falappone PC, Cantatore FP, Muratore M, Lapadula G.

Semin Arthritis Rheum. 2017 Aug;47(1):108-114. doi: 10.1016/j.semarthrit.2017.01.008. Epub 2017 Jan 18.

PMID:
28216195
14.

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.

Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M; REAL Study Group.

Ann Rheum Dis. 2012 Nov;71(11):1820-6. doi: 10.1136/annrheumdis-2011-200838. Epub 2012 Apr 13.

PMID:
22504558
15.

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.

Plasencia C, Pascual-Salcedo D, García-Carazo S, Lojo L, Nuño L, Villalba A, Peiteado D, Arribas F, Díez J, López-Casla MT, Martín-Mola E, Balsa A.

Arthritis Res Ther. 2013 Jul 26;15(4):R79. doi: 10.1186/ar4258.

16.

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.

van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL.

Ann Rheum Dis. 2013 Jun;72(6):895-900. doi: 10.1136/annrheumdis-2012-201338. Epub 2012 Aug 11.

PMID:
22887849
17.

Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.

Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.

J Manag Care Spec Pharm. 2014 Jul;20(7):657-67.

18.

Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.

Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, Chen L, Beukelman T, Saag KG, Curtis JR.

Arthritis Care Res (Hoboken). 2015 May;67(5):624-32. doi: 10.1002/acr.22510.

19.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
20.

Adverse effects of TNF inhibitors in SpA: are they different from RA?

Sampaio-Barros PD, van der Horst-Bruinsma IE.

Best Pract Res Clin Rheumatol. 2014 Oct;28(5):747-63. doi: 10.1016/j.berh.2014.10.001. Epub 2014 Oct 31. Review.

PMID:
25488782

Supplemental Content

Support Center